/
NXTC
$1.75+$0.10 (+6.38%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.9M
4M shares
52-week range
$1.55 – $15.74
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.79%
Moderate
Price (6 mo)
Loading chart…
Change$-93.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.3M | $22.4M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.7M | $34.2M | $46.6M | $0 | $0 | $0 | $0 | $2.2M |
| Gross profit | −$1.7M | −$27.9M | −$24.2M | $0 | $0 | $0 | $0 | −$2.2M |
| Gross margin | — | -439.1% | -108.0% | — | — | — | — | — |
| R&D | $19.8M | $34.2M | $46.6M | $50.2M | $54.2M | $47.9M | $41.5M | $44.9M |
| Operating income | −$23.2M | −$37.5M | −$41.2M | −$70.8M | −$75.9M | −$67.6M | −$59.7M | −$57.6M |
| EBITDA | −$21.1M | −$34.8M | −$37.8M | −$65.1M | −$70.6M | −$59.0M | −$54.3M | −$53.7M |
| Net income | −$22.8M | −$33.7M | −$36.6M | −$69.4M | −$74.7M | −$62.7M | −$55.7M | −$55.8M |
| Net margin | — | -531.5% | -163.6% | — | — | — | — | — |
| EPS (diluted) | -12.04 | -25.79 | -15.95 | -30.15 | -32.32 | -27.04 | -23.88 | -19.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-7.32 | $-7.52–$-7.13 | 2 |
| 2027 | $7M | $-8.31 | $-8.90–$-7.72 | 2 |
| 2028 | $10M | $-5.49 | $-5.49–$-5.49 | 1 |
| 2029 | $23M | $-5.28 | $-5.28–$-5.28 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.70
Price
$1.75
Implied upside
+283%
Peer comparison
NextCure, Inc. Common Stock
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
www.nextcure.com- Employees
- 40
- IPO / List date
- May 9, 2019
- HQ
- BELTSVILLE, MD
Held by traders on TradeandTell
No one on the platform currently holds NXTC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 60,534 | $646.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-07-14 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded NXTC yet.
